Welcome to the e-CCO Library!

P101: Circulating MicroRNA-16 in Inflammatory Bowel Disease Patients - Potential Biomarker to Assess Inflammation
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Atanassova, A.(1);GeorgievaPhD, A.C.(1)*;
Created: Friday, 14 July 2023, 10:48 AM
P101: Fecal calprotectin is increased among patients with pouchitis and increases with increasing endoscopic subscores: Real-world data from a prospectively collected database
Year: 2021
Source: ECCO'21 Virtual
Authors: Ollech, J.(1);Bannon, L.(2);Maharshak, N.(2);Tulchinsky, H.(2);Yanai, H.(1);Dotan, I.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P101: Functional translation of IBD-associated genetic variation in patient-derived intestinal epithelial cells
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

W. Vanhove*1, K. Nys1, I. Arijs1, I. Cleynen2, G. Van Assche1, M. Ferrante1, S. Vermeire1

Created: Friday, 22 February 2019, 9:49 AM
P101: Innate immunity and Crohn’s disease recurrence after surgery
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Saadeh1*, I. Angriman1, A. Kotsafti2, C. Mescoli3, T. Odorizzi1, M. Scarpa2, F. Cavallin2, M. Rugge4, R. Bardini1, I. Castagliuolo5, M. Scarpa2

Created: Thursday, 21 February 2019, 9:14 AM
P101: Interleukin-13 induces polarity defects in the intestinal epithelia
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lebenheim L., Kühnel A., Hering N., Bojarski C., Schulzke J.-D., Siegmund B., Schumann M.

Created: Wednesday, 20 February 2019, 10:36 AM
P101: Isosteviol Attenuates Dextran Sulfate Sodium-Induced Colitis by Maintaining the Intestinal Barrier Through PDK1/AKT/NF-κB Signaling
Year: 2022
Source: ECCO'22
Authors: Yao, L.(1);Cao, Q.(1);
Created: Friday, 11 February 2022, 3:52 PM
P101: Simple five-point classification of MR enterocolonography for Crohn’s disease based on enteroscopic findings
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Fujii*1, Y. Kitazume2, K. Takenaka1, K. Suzuki1, M. Motobayashi1, E. Saito1, M. Nagahori1, K. Ohtsuka1, M. Watanabe1

Created: Friday, 22 February 2019, 9:41 AM
P102 Host gene background and concentration influence the butyrate effect on modulating IECs proliferation
Year: 2020
Source:

ECCO'20 Vienna

Authors:

H. He1, J. Hu2, W. Wang2, M. Zhang2, M. Zheng2, X. Peng2, Y. Zhang2, M. Zhou2, T. Liu2, J. Zhao2, Q. Zhang2, M. Zhi2,1

Created: Thursday, 30 January 2020, 10:12 AM
P102: α-Defensins(αDef) 1-3 are specific plasmatic markers for Crohn’s disease (CD) at diagnosis and tissue α-Def 5 methylation is a pathogenic mechanism for αDef-5 down regulation in CD.
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

E. Cerrillo1, I. Moret-Tatay2,3, M. Iborra1,2, E. Sáez-González1, E. Busó4, D. Ramos5, L. Tortosa1, P. Nos1,3, B. Beltrán*1,3

Created: Friday, 22 February 2019, 9:49 AM
P102: A small molecule selective integrin α4β7 inhibitor demonstrates efficacy in a chronic model of Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Redhu, N.S.(1)*;Rowe, M.(1);Lee, D.(2);Jain, D.(1);Sang, A.(1);Granata, D.(1);Harrison, B.(3);Cui, D.(2);Bursavich, M.(3);Ray, A.S.(1);Lippa, B.(3);Rogers, B.N.(3);Wong , J.(1);
Created: Friday, 14 July 2023, 10:48 AM
P102: Changes in serum immune protein profiles following vedolizumab therapy in Inflammatory Bowel Disease.
Year: 2022
Source: ECCO'22
Authors: O'Connell, J.(1,2);O'Connell, F.(2);O'Sullivan, J.(2);Kevans, D.(1,2,3);
Created: Friday, 11 February 2022, 3:52 PM
P102: Hypoxia reduces inflammation through the downregulation of NLRP3/mTOR signaling and the activation of autophagy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Cosin-Roger J.*1, Simmen S.1, Melhem H.1, Atrott K.1, Frey-Wagner I.1, Hausmann M.1, de Vallière C.1, Spalinger M.R.1, Spielmann P.2,3, Wagner R.H.2,3, Zeitz J.1, Vavricka S.R.1, Rogler G.1, Ruiz P.A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P102: Increased abundance of gut microbial virulence genes and pro-inflammatory pathways during Crohn’s disease exacerbations
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Klaassen*, F. Imhann, V. Collij, A. Vich Vila, R. Gacesa, J. Fu, A. Zhernakova, C. Wijmenga, R. Weersma

Created: Thursday, 21 February 2019, 9:14 AM
P102: Outcomes of coronavirus disease 2019 among patients with inflammatory bowel diseases and the influence of IBD-related medications– A Danish prospective population-based cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Attauabi, M.(1,2,3);Poulsen, A.(4);Kajbæk Verner-Andersen, M.(5);Rosager Hansen, M.(6);Pedersen, N.(7);Pilegaard Prahm, A.(4);Berg Lødrup, A.(8);Haderselv, K.(9);Larsen, L.(10);Jess, T.(10,11);Glerup, H.(12);Molazahi, A.(13);Mathiassen Oppfeldt, A.(14);Dahlerup, J.F.(15);Lodberg Hvas, C.(15);Neumann, A.(16);Wase, A.(16);Dam Jensen, M.(17);Nathan, T.(17);Jensen, S.(17);Theede, K.(1,3);Kiszka-Kanowitz, M.(1,3);Benedict Seidelin, J.(2);Burisch, J.(1,3);
Created: Wednesday, 2 June 2021, 4:12 PM
P102: Subclinical atherosclerosis assessed by coronary artery calcium score in patients with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Rocha*1, C. Nomura2, M. Rocha2, B. Lopes2, M. Azevedo1, A. Carlos1, F. Carrillo1, A. Damiao1, A. Sipahi1, A. Leite1

Created: Friday, 22 February 2019, 9:41 AM
P103 The treatment effect of tonsil-derived mesenchymal stem cells (T-MSCs) via regulating programmed death-1/programmed death ligand-1 (PD-1/PD-L1) in ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E.M. Song, Y.H. Joo, J.Y. Lim, A.R. Choe, C.H. Tae, C.M. Moon, S.E. Kim, H.K. Jung, K.N. Shim, S.A. Jung

Created: Thursday, 30 January 2020, 10:12 AM
P103: Colitis-associated faecal miRNAs are mediators of host-microbiota interactions and key regulators of intestinal permeability and inflammation
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Casado-Bedmar, M.(1)*;Roy, M.(1);Hugot, J.P.(1);Le Gall, M.(1);Chassaing, B.(2);Viennois, E.(1);
Created: Friday, 14 July 2023, 10:48 AM
P103: Degradation and formation of type III, IV and V collagen are associated with disease activity, disease severity and disease extension in patients with ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. H. Mortensen*1, V. Domislovic2, M. A. Karsdal1, M. Brinar2, Z. Krznaric2, T. Manon-Jensen1

Created: Friday, 22 February 2019, 9:41 AM
P103: Evaluation of efficacy of new vectors for siRNA CYCLIN D1 and E2F1 delivery in control of cancer progression in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Russo I.*1, Bochicchio S.2, Piazza O.3, Barba A.A.2, Lamberti G.4, Carrizzo A.5, Zeppa P.6, Vecchione C.6, Iovino P.6, Ciacci C.6

Created: Wednesday, 20 February 2019, 10:36 AM
P103: Identifying CES-1 positive myeloid cells with mass cytometry as a potential therapeutic target for Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: HagemanMD, I.(1);Elfiky, A.(2);Becker, M.(2);Joustra, V.(1);Buskens, C.(3);Li Yim, A.(2);Hakvoort, T.(2);Verhoeff, J.(4);Garcia Vallejo, J.(4);D'Haens, G.(1);Wildenberg, M.(2);De Jonge, W.(2);
Created: Friday, 11 February 2022, 3:52 PM